N
VOR icon

Nuveen’s Vor Biopharma VOR Stock Holding History

Nuveen’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,575
Closed -$169K – 3421
2024
Q1 		$169K Hold
3,575
– – ﹤0.01% 3209
2023
Q4 		$161K Hold
3,575
– – ﹤0.01% 3243
2023
Q3 		$152K Hold
3,575
– – ﹤0.01% 3079
2023
Q2 		$221K Buy
+3,575
New +$326K ﹤0.01% 3078
2022
Q2 		– Sell
-2,765
Closed -$422K – 3492
2022
Q1 		$422K Buy
2,765
+53
+2% +$9.02K ﹤0.01% 3061
2021
Q4 		$666K Sell
2,712
-214
-7% -$61.7K ﹤0.01% 2992
2021
Q3 		$899K Buy
2,926
+516
+21% +$153K ﹤0.01% 3027
2021
Q2 		$899K Buy
2,410
+334
+16% +$165K ﹤0.01% 3047
2021
Q1 		$1.79M Buy
+2,076
New +$1.76M ﹤0.01% 2668

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen's VOR Position: Q2 2024 in Review

Nuveen sold out of Vor Biopharma (VOR) in Q2 2024, closing a stake of 3,575 shares — an estimated $169K sold.

Nuveen first reported a position in VOR in Q1 2021 and held it in 9 quarters. The position peaked at $1.79M in Q1 2021. 71 funds tracked by Wall St. Rank hold VOR as of Q2 2024.

  • Nuveen reported no remaining Vor Biopharma position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 3,575 Vor Biopharma shares in Q2 2024, an estimated $169K.
  • Nuveen first reported a position in Vor Biopharma in Q1 2021 and held it in 9 quarters.
  • Nuveen's Vor Biopharma position peaked at $1.79M in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.